top of page


29 February 2024

Honouring Rare Disease Day: The Battle Against Multiple Myeloma and AL Amyloidosis

1 June 2023

Inside the KappaMab manufacturing process

26 May 2023

Karen Wilde, myeloma patient story - Short Video

26 May 2023

Karen Wilde, myeloma patient story - Long Video

3 May 2023

Our value inflection points between Q2 2023 and FY 2024

3 May 2023

The competitive advantage of our immunotherapies explained

3 May 2023

Meet our team - An introduction to Dr Geoffrey Nichol

22 December 2022

The latest on our CAR-T technology and more, presented at Myeloma Australia’s 4th National Myeloma Workshop

21 December 2022

Novel antigens LMA and KMA are expressed on malignant bone marrow plasma cells from patients at all stages of multiple myeloma 

15 December 2022

What makes our immunotherapies different on the large and growing multiple myeloma treatment market

13 October 2022

HaemaLogiX company overview with CEO Bryce Carmine - October, 2022

15 August 2022

Chief Manufacturing and Development Officer Tertia Dex explains the KappaMab manufacturing process

15 March 2022

HaemaLogiX's Mary Sartor's presentation to the 63rd Annual ASH Annual Meeting in Atlanta, Georgia 2021

16 February 2022

How KappaMab works. KappaMab is a monoclonal antibody developed by HaemaLogiX to treat blood cancers, with an initial focus on multiple myeloma.

bottom of page